JonesResearch downgraded Clearside Biomedical (CLSD) to Hold from Buy without a price target after the company said it is exploring strategic alternatives to maximize shareholder value. The firm finds it unclear if this strategic review will result in a transaction. It cites Clearside’s “unclear path ahead” for the downgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Hold Rating for Clearside Biomedical Amid Strategic Uncertainty and Financial Constraints
- Clearside Biomedical Explores Strategic Alternatives Amid Economic Challenges
- Clearside Biomedical transitions all employees to consulting roles
- Clearside Biomedical to explore strategic alternatives to advance SCS platform
- Clearside Biomedical Approves Share Increase at Annual Meeting